Variant · Expression
FGFR4 Overexpression
CI-VAR-00003177Explore in graph →CIViC 2167
Curated evidence
Evidence by cancer (5 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 24124571
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Alveolar Rhabdomyosarcoma1 | ||||||||
| FGFR4 Overexpression | Ponatinib | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID7137Indeed, cell lines expressing the highest levels of FGFR4 (above a relative level of six) were the most sensitive to ponatinib (Figure 1C, p = 0.0344). These results, therefore, suggest that increased… (full text at CIViC) PMID 24124571 · Li et al., 2013 · Open in CIViC | civic |
| HER2-Positive Breast Carcinoma1 | ||||||||
| FGFR4 Overexpression | Dovitinib + FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074Substitutes | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID5828ERBB2-positive breast cancer cell lines including MDA-MB-361 and MDA-MB-453 were found to display outlier expression of FGFR4. Targeting FGFR4 in FGFR4 overexpressing ERBB2-positive breast cancer samp… | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available